Liminal Biosciences Profit Margin

Liminal Biosciences (LMNL) currently reports a profit margin of 71.95% as of June 2023. That compares with 9107.96% in the prior-year period — down 99.2% year over year. That is above the Healthcare sector average of 14.34%. Use the charts on this page to explore Liminal Biosciences's profit margin history and peer comparisons.

Liminal Biosciences's profit margin decreased from 9107.96% to 71.95% — a 99.2% year-over-year decrease (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Liminal Biosciences's profit margin of 71.95% is higher than the Healthcare sector average of 14.34%. That is roughly 401.6% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Liminal Biosciences's current 71.95% should be judged against Healthcare norms (sector average: 14.34%) and against LMNL's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 71.95%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 14.34%. From there, open related valuation or income-statement pages for Liminal Biosciences, and consider following LMNL for alerts when major investors trade the stock.